ALLMedicine™ Lymphoma Center
Research & Reviews 35,459 results
https://doi.org/10.1111/ejh.13606
European Journal of Haematology; Zduniak A, Mihailescu SD et. al.
Feb 24th, 2021 - We conducted a retrospective study to analyze the prognostic factors impacting the overall survival (OS) and progression-free survival (PFS) of diffuse large B cell lymphoma (DLBCL) patients undergoing first-line therapy and admitted to intensive ...
https://doi.org/10.1186/s12977-021-00550-8 10.1073/pnas.77.12.7415 10.1038/sj.onc.1208980 10.1182/blood.V50.3.481.481 10.3389/fmicb.2017.01425/full 10.1016/S0140-6736(85)92734-5 10.1016/S0140-6736(86)91298-5 10.1038/294268a0 10.1002/ijc.2910330202 10.1002/ijc.2910430618 10.1073/pnas.1521629112 10.1038/nrdp.2015.12 10.1186/s12977-018-0454-x 10.1186/s12889-016-3366-5 10.1016/S0140-6736(18)30974-7 10.1073/pnas.1009635107 10.3390/v8030074 10.3389/fimmu.2018.00260/full 10.1038/s41598-018-29391-w 10.1126/science.6316502 10.1128/JCM.30.4.905-910.1992 10.1128/JVI.75.18.8461-8468.2001 10.1128/JVI.01799-15 10.1016/j.virusres.2019.197653 10.1111/j.1749-6632.2011.06304.x 10.1128/JVI.06993-11 10.1038/nm.2065 10.1182/blood-2004-07-2850 10.1074/jbc.M502639200 10.1182/blood-2008-03-136770 10.3389/fmicb.2019.02147 10.3389/fmicb.2016.01765 10.1089/dna.2017.3639 10.3389/fcimb.2018.00362 10.1074/jbc.A117.793521 10.3390/v9070176 10.1186/s40169-018-0204-7 10.1038/s41598-017-17765-5 10.1007/s11481-019-09865-y 10.4161/auto.5222 10.1007/s13238-014-0104-6 10.1074/jbc.M113.515361 10.1371/journal.ppat.1005018 10.1523/JNEUROSCI.3207-14.2015 10.1038/onc.2013.552 10.1038/s41598-017-08736-x 10.1016/j.cellsig.2013.09.010 10.3389/fmicb.2016.00139 10.1074/jbc.M114.549659 10.1074/jbc.M112.438895 10.1074/jbc.M115.662171 10.1073/pnas.1521230113 10.1098/rstb.2016.0479 10.1038/s41556-018-0049-8 10.1158/0008-5472.CAN-10-4455 10.1186/s12964-015-0086-x 10.1172/JCI87105 10.3389/fendo.2017.00194/full 10.1016/j.immuni.2013.10.020 10.1016/j.cell.2010.01.028 10.1016/j.virol.2015.03.042 10.1186/1755-1536-4-21 10.1038/s41598-017-17765-5 10.3389/fcimb.2020.00006 10.1111/aji.12860 10.1038/nri3831 10.1038/nri.2016.95 10.1242/jcs.154906 10.1186/s12977-016-0307-4 10.1016/j.cell.2010.02.015 10.1080/13547500701791719 10.1084/jem.20081165 10.1681/ASN.2011111077 10.1038/ncomms1180 10.3389/fimmu.2018.01463 10.3389/fimmu.2018.00534 10.1586/1744666X.2014.894886 10.1016/j.ctrv.2017.08.004 10.1155/2019/6252138 10.1016/j.jid.2018.06.188 10.1007/s12020-012-9839-0 10.3389/fmicb.2012.00378 10.1128/JVI.02147-12 10.1007/s11060-013-1084-8 10.1038/s41556-018-0250-9 10.1128/JCM.38.11.4049-4057.2000 10.1016/S1386-6532(99)00087-6 10.1084/jem.177.6.1567 10.1073/pnas.95.13.7568 10.1086/317932 10.1080/135502802317247811 10.1371/journal.ppat.1002480 10.1371/journal.ppat.1007589 10.3390/ijms20061445 10.1182/blood-2010-11-321364 10.5045/br.2017.52.2.106 10.3389/fmicb.2017.02563 10.1016/j.tins.2005.06.008 10.1161/STROKEAHA.107.513150 10.3389/fncel.2018.00494/full
Retrovirology Pinto DO, Al Sharif S et. al.
Feb 24th, 2021 - The Human T-cell Lymphotropic Virus Type-1 (HTLV-1) is a blood-borne pathogen and etiological agent of Adult T-cell Leukemia/Lymphoma (ATLL) and HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). HTLV-1 has currently infected up ...
https://doi.org/10.1136/bcr-2020-240242
BMJ Case Reports; Yang Y, Canepa C
Feb 24th, 2021 - A previously fit and well 76-year-old man, presented with distal lower limb sensory symptoms suggestive of peripheral sensory neuropathy, associated with positive anti-MAG antibodies (myelin associated glycoprotein) and IgM paraprotein. Bone marro...
https://doi.org/10.1093/ajcp/aqaa249
American Journal of Clinical Pathology; Abukhiran I, Syrbu SI et. al.
Feb 24th, 2021 - Follicular helper T cell (TFH) markers are expressed in angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma of the TFH phenotype (PTCL-TFH). However, differential expression and coexpression of these markers in benign and othe...
https://doi.org/10.1007/s00277-021-04448-5 10.1016/S0140-6736(02)08938-9 10.1016/0140-6736(93)92411-l 10.1182/blood-2011-10-388058 10.1182/blood.v97.3.616 10.1093/annonc/mdf221 10.1093/annonc/mdm090 10.3324/haematol.10661 10.3109/10428194.2010.491137 10.1200/JCO.2012.45.3308 10.1182/blood-2017-11-815183 10.1016/S1470-2045(17)30912-9 10.1200/JCO.2016.66.4466 10.1016/j.achaem.2015.07.094 10.1200/JCO.2013.54.8800 10.1002/cncr.21587 10.1007/s00277-010-1113-z 10.1002/cncr.32640 10.1016/j.bbmt.2015.07.018 10.1056/NEJMoa1411087 10.1200/JCO.2016.67.3467 10.1200/JCO.2016.72.1316 10.1182/blood-2016-09-738385 10.1038/bmt.2017.158
Annals of Hematology; Swoboda R, Giebel S et. al.
Feb 24th, 2021 - The optimal salvage therapy in relapsed/refractory Hodgkin lymphoma (R/R HL) has not been defined so far. The goal of this multicenter retrospective study was to evaluate efficacy and safety of BGD (bendamustine, gemcitabine, dexamethasone) as a s...
Guidelines 107 results
https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma
FDA
Jul 23rd, 2020 - The Food and Drug Administration granted accelerated approval to brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company), a CD19-directed genetically modified autologous T cell immunotherapy, for the treatment of adult patients with relapsed ...
https://www.medpagetoday.com/meetingcoverage/asco/86783
May 30th, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192083/
Leukemia Research; Paneesha S
Apr 29th, 2020 - The global pandemic of the novel coronavirus SARS-CoV-2 represents one of the greatest infectious challenges to human health in recent history. At the current time over 3.2 million people have been infected and this has proved fatal in over 230,00...
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-ibrutinib-plus-rituximab-chronic-lymphocytic-leukemia
FDA
Apr 20th, 2020 - The Food and Drug Administration expanded the indication of ibrutinib (IMBRUVICA, Pharmacyclics LLC) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106983
Journal of Clinical Oncology : Official Journal of the Am... Jaffe ES, Ashar BS et. al.
Feb 11th, 2020 - To provide guidelines for the accurate pathologic diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected BIA-ALCL, and the pathologic evaluation of the capsulecto...
Drugs 111 results see all →
Clinicaltrials.gov 36,709 results
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/treatment-with-loxo-305-results-in-durable-efficacy-in-heavily-pretreated-patients-with-cllsll/
Feb 24th, 2021 - Despite the marked efficacy of ibrutinib, acalabrutinib, and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), treatment failure can occur through the development of resistance. In addition, patients in whom Bruton’s...
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/overcoming-cd58-loss-may-be-promising-path-to-overcoming-resistance-to-car-t-cell-therapies/
Feb 24th, 2021 - Engineering chimeric antigen receptor (CAR) T cells to overcome CD58 loss may be a way to boost responses in patients with diffuse large B-cell lymphoma (DLBCL) who do not respond to treatment with axicabtagene ciloleucel and other CAR T-cell ther...
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/zuma-5-axicabtagene-ciloleucel-elicits-response-in-indolent-non-hodgkin-lymphoma/
Feb 24th, 2021 - In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American Society of Hematology (ASH) Annual Meeting & E...
https://doi.org/10.1111/ejh.13606
European Journal of Haematology; Zduniak A, Mihailescu SD et. al.
Feb 24th, 2021 - We conducted a retrospective study to analyze the prognostic factors impacting the overall survival (OS) and progression-free survival (PFS) of diffuse large B cell lymphoma (DLBCL) patients undergoing first-line therapy and admitted to intensive ...
https://doi.org/10.1186/s12977-021-00550-8 10.1073/pnas.77.12.7415 10.1038/sj.onc.1208980 10.1182/blood.V50.3.481.481 10.3389/fmicb.2017.01425/full 10.1016/S0140-6736(85)92734-5 10.1016/S0140-6736(86)91298-5 10.1038/294268a0 10.1002/ijc.2910330202 10.1002/ijc.2910430618 10.1073/pnas.1521629112 10.1038/nrdp.2015.12 10.1186/s12977-018-0454-x 10.1186/s12889-016-3366-5 10.1016/S0140-6736(18)30974-7 10.1073/pnas.1009635107 10.3390/v8030074 10.3389/fimmu.2018.00260/full 10.1038/s41598-018-29391-w 10.1126/science.6316502 10.1128/JCM.30.4.905-910.1992 10.1128/JVI.75.18.8461-8468.2001 10.1128/JVI.01799-15 10.1016/j.virusres.2019.197653 10.1111/j.1749-6632.2011.06304.x 10.1128/JVI.06993-11 10.1038/nm.2065 10.1182/blood-2004-07-2850 10.1074/jbc.M502639200 10.1182/blood-2008-03-136770 10.3389/fmicb.2019.02147 10.3389/fmicb.2016.01765 10.1089/dna.2017.3639 10.3389/fcimb.2018.00362 10.1074/jbc.A117.793521 10.3390/v9070176 10.1186/s40169-018-0204-7 10.1038/s41598-017-17765-5 10.1007/s11481-019-09865-y 10.4161/auto.5222 10.1007/s13238-014-0104-6 10.1074/jbc.M113.515361 10.1371/journal.ppat.1005018 10.1523/JNEUROSCI.3207-14.2015 10.1038/onc.2013.552 10.1038/s41598-017-08736-x 10.1016/j.cellsig.2013.09.010 10.3389/fmicb.2016.00139 10.1074/jbc.M114.549659 10.1074/jbc.M112.438895 10.1074/jbc.M115.662171 10.1073/pnas.1521230113 10.1098/rstb.2016.0479 10.1038/s41556-018-0049-8 10.1158/0008-5472.CAN-10-4455 10.1186/s12964-015-0086-x 10.1172/JCI87105 10.3389/fendo.2017.00194/full 10.1016/j.immuni.2013.10.020 10.1016/j.cell.2010.01.028 10.1016/j.virol.2015.03.042 10.1186/1755-1536-4-21 10.1038/s41598-017-17765-5 10.3389/fcimb.2020.00006 10.1111/aji.12860 10.1038/nri3831 10.1038/nri.2016.95 10.1242/jcs.154906 10.1186/s12977-016-0307-4 10.1016/j.cell.2010.02.015 10.1080/13547500701791719 10.1084/jem.20081165 10.1681/ASN.2011111077 10.1038/ncomms1180 10.3389/fimmu.2018.01463 10.3389/fimmu.2018.00534 10.1586/1744666X.2014.894886 10.1016/j.ctrv.2017.08.004 10.1155/2019/6252138 10.1016/j.jid.2018.06.188 10.1007/s12020-012-9839-0 10.3389/fmicb.2012.00378 10.1128/JVI.02147-12 10.1007/s11060-013-1084-8 10.1038/s41556-018-0250-9 10.1128/JCM.38.11.4049-4057.2000 10.1016/S1386-6532(99)00087-6 10.1084/jem.177.6.1567 10.1073/pnas.95.13.7568 10.1086/317932 10.1080/135502802317247811 10.1371/journal.ppat.1002480 10.1371/journal.ppat.1007589 10.3390/ijms20061445 10.1182/blood-2010-11-321364 10.5045/br.2017.52.2.106 10.3389/fmicb.2017.02563 10.1016/j.tins.2005.06.008 10.1161/STROKEAHA.107.513150 10.3389/fncel.2018.00494/full
Retrovirology Pinto DO, Al Sharif S et. al.
Feb 24th, 2021 - The Human T-cell Lymphotropic Virus Type-1 (HTLV-1) is a blood-borne pathogen and etiological agent of Adult T-cell Leukemia/Lymphoma (ATLL) and HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). HTLV-1 has currently infected up ...
News 2,007 results
https://www.medscape.com/viewarticle/945454
Feb 8th, 2021 - NEW YORK (Reuters Health) - An international team has developed and validated a prognostic index specific for Burkitt lymphoma to aid in risk stratification, interpretation of clinical trials, and targeted development of novel therapeutic strategi...
https://www.medscape.com/viewarticle/945426
Feb 7th, 2021 - The US Food and Drug Administration (FDA) has granted accelerated approval to umbralisib (Ukoniq) for the treatment of adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and...
https://reference.medscape.com/viewarticle/944100
Jan 31st, 2021 - Waldenström macroglobulinemia (WM) is an indolent subtype of non-Hodgkin lymphoma (NHL) that affects small lymphocytes. WM is rare, accounting for approximately 2% of hematologic malignancies with 1500 cases diagnosed per year in the United States...
https://www.medscape.com/viewarticle/943428
Dec 30th, 2020 - The US Food and Drug Administration (FDA) granted accelerated approval on July 24, 2020, for the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus) for the treatment of adults with relapsed or refractory mantle cel...
https://www.medscape.com/viewarticle/942494
Dec 10th, 2020 - For the first time, a chimeric antigen receptor (CAR) therapy has yielded a high response rate among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), including patients with follicular lymphoma (FL) and marginal zone lymphom...
